Economic analysis of opportunities to accelerate Alzheimer’s disease research and development

The development of disease-modifying treatments for Alzheimer's disease (AD) faces a number of barriers. Among these are the lack of surrogate biomarkers, the exceptional size and duration of clinical trials, difficulties in identifying appropriate populations for clinical trials, and the limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Troy J, O'Connor, Alan C, Link, Albert N, Beaulieu, Travis J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285871/
https://www.ncbi.nlm.nih.gov/pubmed/24673372
http://dx.doi.org/10.1111/nyas.12417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285871/
https://www.ncbi.nlm.nih.gov/pubmed/24673372
http://dx.doi.org/10.1111/nyas.12417

Ejemplares similares